Clinical Trials Browser

Phase 1/2 × duvelisib × 90 days × Clear all

NCT02158091 2026-02-13

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Phase 1/2 Active not recruiting

32 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell